Januvia news from FierceBiotech

Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...

Following a label change, Novartis has won EU approval for its trouble diabetes drug Galvus. It will be used in combination with some of the most frequently prescribed oral anti-diabetes medicines. Read more...

Novartis is staring at some serious problems rolling out its diabetes drug Galvus. New data showing patients taking higher doses of the drug--100 mg--demonstrated more frequent enzyme elevation Read more...

> CODA Genomics garnered $7 million in its third round of venture funding. OVP Venture Partners led the round with existing investors Monitor Ventures, Tech Coast Angels, and Life Science Angels Read more...

Press Release: Positive Opinion For Type 2 Diabetes Treatment, JANUVIA

Read more...

> The CHMP in Europe issued a positive opinion for the diabetes therapy Januvia. Release

> Lentigen and Wave Biotech have inked a deal in which Wave will provide process and equipment expertise for Lentigen's manufacturing platform based on its lentiviral vector technology. …

Read more...

> A new study of Cephalon's Trisenox for acute promyelocytic leukemia demonstrated increased survival time. "The results of this study showing a survival benefit associated with the use of Trisenox in patients with APL are an important development for physicians and patients, as demonstrated by the urgency to disseminate the results to clinicians in an expedited manner," says Dr. Lesley Russell, executive vice president of …

Read more...

Germany's Merck KGaA has agreed to pay €25 million up front and up to €190 million in total to license Glenmark's DPP-4 inhibitor, GRC 8200, which is in Phase II trials. Glenmark retains marketing rights to India while Merck KGaA gains North America, Europe and Japan.

- see the press release on the pact

ALSO: As expected, …

Read more...

The Financial Times notes that Merck's Januvia could be approved by the FDA as early as today. Januvia is a new type of diabetes drug that regulates sugar and insulin production. Analysts expect Januvia to be a blockbuster, which would be a welcome relief to the embattled Merck. But Merck won't own the DPP-IV inhibitor market for long. Novartis' Galvus is expected to get an approval next month.

- here's the …

Read more...

Researchers say that exenatide proved as effective as NovoNordisk's NovoMix 30 in improving blood sugar levels in patients with type 2 diabetes who do not respond to two standard therapies. Eighteen percent of the patients given exenatide--developed by Eli Lilly and Amylin Pharmaceuticals--achieved recommended blood sugar levels compared to nine percent in the NovoMix 30 group. And the exenatide patients lost weight on average, compared to a weight gain among those taking …

Read more...